Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
Details : Kloxxado delivers 8 mg of naloxone hydrochloride, an opioid antagonist, approved as a ready to use nasal spray to reverse the effects of opioid overdose.
Product Name : Kloxxado
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 20, 2025
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Emergent BioSolutions
Deal Size : Undisclosed
Deal Type : Agreement
Emergent BioSolutions Gains Exclusive Rights to KLOXXADO® Nasal Spray
Details : Under the terms of the agreement, Emergent will be responsible for the distribution of Kloxxado (Naloxone HCl). It is being indicated for the treatment of known or suspected opioid overdose.
Product Name : Kloxxado
Product Type : Controlled Substance
Upfront Cash : Undisclosed
January 14, 2025
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Emergent BioSolutions
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Liraglutide
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
US FDA Approves Hikma's Generic Version of Novo's Diabetes Drug Victoza
Details : Victoza-Generic (liraglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is indicated for the treatment of patients with type 2 diabetes mellitus.
Product Name : Victoza-Generic
Product Type : Peptide
Upfront Cash : Inapplicable
December 26, 2024
Lead Product(s) : Liraglutide
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Furosemide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hikma launches Furosemide Injection, USP, in the US
Details : Furosemide injection is indicated in adults & pediatric patients for the treatment of edema associated with heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome.
Product Name : Furosemide Injection-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 09, 2024
Lead Product(s) : Furosemide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hikma Announces US Launch of COMBOGESIC® IV
Details : Combogesic IV (acetaminophen & ibuprofen) is an opioid-free pain relief medicine approved for adults to relieve mild to moderate pain and manage moderate to severe pain as an adjunct to opioids.
Product Name : Combogesic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 02, 2024
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : CanariaBio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Hikma gains right for MAb-B43.13 (oregovomab), a murine monoclonal antibody, being tested in combination with carboplatin and paclitaxel for patients with advanced ovarian cancer, in the Middle East and North Africa (MENA) region.
Product Name : MAb-B43.13
Product Type : Antibody
Upfront Cash : Undisclosed
October 10, 2023
Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : CanariaBio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Dobutamine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hikma Exceeds 150 Injectable Medicines in The US with Launch of Dobutamine Injection, USP
Details : Dobutamine injection stimulates heart muscle and improves blood flow by helping the heart pump better, which is used short-term to treat cardiac decompensation due to weakened heart muscle.
Product Name : Dobutamine-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 14, 2023
Lead Product(s) : Dobutamine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olopatadine Hydrochloride,Mometasone Furoate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hikma Launches Ryaltris™ Seasonal Allergic Rhinitis Nasal Spray in The US
Details : The efficacy and safety of RYALTRIS (olopatadine hydrochloride) was established in a robust clinical studies program in over 4,000 patients with SAR. Twice-daily RYALTRIS™ provided statistically significant improvement in both nasal and ocular symptoms...
Product Name : Ryaltris
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 30, 2022
Lead Product(s) : Olopatadine Hydrochloride,Mometasone Furoate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paracetamol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Hikma Pharmaceuticals
Deal Size : $425.0 million
Deal Type : Acquisition
Hikma Completes Acquisition of Custopharm
Details : The combination with Custopharm enhances Hikma’s R&D capabilities and pipeline and expands Hikma’s differentiated US portfolio to close to 130 commercialised injectable medicines – a more than fivefold increase over the last decade, including Aceta...
Product Name : Acetaminophen-Generic
Product Type : Other Small Molecule
Upfront Cash : $375.0 million
April 21, 2022
Lead Product(s) : Paracetamol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Hikma Pharmaceuticals
Deal Size : $425.0 million
Deal Type : Acquisition
Lead Product(s) : Hydralazine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Hydralazine Hydrochloride Injection, USP is indicated for severe essential hypertension when the drug cannot be given orally or when there is an urgent need to lower blood pressure.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 05, 2021
Lead Product(s) : Hydralazine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable